Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression

BACKGROUND Prostate ducts and acini whose lumens are filled with malignant cells represent a well‐recognized histological pattern recently termed intraductal carcinoma of the prostate (IDC‐P). These tumors are often associated with rapid disease progression, and most recur after radical surgery. Con...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Prostate 2000-09, Vol.44 (4), p.265-270
Hauptverfasser: Dawkins, Hugh J.S., Sellner, Loryn N., Turbett, Gavin R., Thompson, Colin A., Redmond, Sharon L., McNeal, John E., Cohen, Ronald J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 270
container_issue 4
container_start_page 265
container_title The Prostate
container_volume 44
creator Dawkins, Hugh J.S.
Sellner, Loryn N.
Turbett, Gavin R.
Thompson, Colin A.
Redmond, Sharon L.
McNeal, John E.
Cohen, Ronald J.
description BACKGROUND Prostate ducts and acini whose lumens are filled with malignant cells represent a well‐recognized histological pattern recently termed intraductal carcinoma of the prostate (IDC‐P). These tumors are often associated with rapid disease progression, and most recur after radical surgery. Controversy exists as to whether IDC‐P should be recognized as a separate entity, an extension of high‐grade dysplasia (PIN) or invasive carcinoma as described by the Gleason grading system. This study investigates the use of molecular markers in defining the position of IDC‐P in the evolutionary hierarchy of prostate cancer progression. METHODS IDC‐P, high‐grade dysplasia, and invasive cancers from a cohort of 20 selected radical prostatectomy specimens were screened for loss of heterozygosity (LOH), using 12 polymorphic microsatellite markers frequently lost in prostate cancer. RESULTS LOH was absent in Gleason grade 3 cancer, infrequent in high‐grade dysplasia (9%) and Gleason grade 4 cancer (29%), but common in IDC‐P (60%). In IDC‐P, and to a lesser extent Gleason grade 4 cancers, multiple sites of allelic loss in individual cases were usual. CONCLUSIONS Allelic instability provides further evidence that IDC‐P is not a simple extension of dysplasia, nor does it represent invasion of Gleason grade 3 cancers into the ductal/acinar system. IDC‐P and Gleason grade 4 cancer represent late but possibly separate events in prostate cancer evolution. Prostate 44:265–270, 2000. © 2000 Wiley‐Liss, Inc.
doi_str_mv 10.1002/1097-0045(20000901)44:4<265::AID-PROS1>3.0.CO;2-I
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71764963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71764963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4901-fce52775fc2b9d0e906e09fa32b7a638598412119aedaacebaddc400f79a1d333</originalsourceid><addsrcrecordid>eNqVkt9u0zAUhyMEYmXwCsgXCHXSUmzHiZuCkKYURqSydgzE5ZHrnLSG_ClxstHn4gVxSClccINvIjm_851jf_a8mNEJo5S_YDSWPqUiHHPqVkzZmRAz8YpH4Wx2kc791YflDXsdTOgkWb7kfnrPGx1r7nsjyiX1BQvkiffI2i-UOirlD70TFwqZmMYj78fc2NZUujV1RdbY3iFWxFRto7JOt6ogWjXaVHWpSJ2Tdotk19S2VS2ScTpP_NXZOdmazdbfuAok2d7uCmWNIuNVeuX-qSpzuFu3dXssNZq4bFUf0eeks6bakLIuUHeFakipmq_Y2L6nVpXGpq_dNGitm_Ox9yBXhcUnh--p9-ntm4_JO3-xvEyTi4WvhbsqP9cYcinDXPN1nFGMaYQ0zlXA11JFwTSMp4JxxmKFmVIa1yrLtKA0l7FiWRAEp97zget6f-vQtlAaq7EoVIV1Z0EyGYk46oPXQ1C7A9oGc9g1xh1hD4xCbxJ6K9Bbgd8mQQgQ4EwCOJPwyyQEQCFZAofUMZ8emnfrErO_iIM6F3h2CCirVZE37p6M_ZMTkk4j5mI3Q-zOFLj_r8H-Ndew4aj-QHWvB78fqc4aRDKQIXy-uoTrKJA8iRbwPvgJutvV9w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71764963</pqid></control><display><type>article</type><title>Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Dawkins, Hugh J.S. ; Sellner, Loryn N. ; Turbett, Gavin R. ; Thompson, Colin A. ; Redmond, Sharon L. ; McNeal, John E. ; Cohen, Ronald J.</creator><creatorcontrib>Dawkins, Hugh J.S. ; Sellner, Loryn N. ; Turbett, Gavin R. ; Thompson, Colin A. ; Redmond, Sharon L. ; McNeal, John E. ; Cohen, Ronald J.</creatorcontrib><description>BACKGROUND Prostate ducts and acini whose lumens are filled with malignant cells represent a well‐recognized histological pattern recently termed intraductal carcinoma of the prostate (IDC‐P). These tumors are often associated with rapid disease progression, and most recur after radical surgery. Controversy exists as to whether IDC‐P should be recognized as a separate entity, an extension of high‐grade dysplasia (PIN) or invasive carcinoma as described by the Gleason grading system. This study investigates the use of molecular markers in defining the position of IDC‐P in the evolutionary hierarchy of prostate cancer progression. METHODS IDC‐P, high‐grade dysplasia, and invasive cancers from a cohort of 20 selected radical prostatectomy specimens were screened for loss of heterozygosity (LOH), using 12 polymorphic microsatellite markers frequently lost in prostate cancer. RESULTS LOH was absent in Gleason grade 3 cancer, infrequent in high‐grade dysplasia (9%) and Gleason grade 4 cancer (29%), but common in IDC‐P (60%). In IDC‐P, and to a lesser extent Gleason grade 4 cancers, multiple sites of allelic loss in individual cases were usual. CONCLUSIONS Allelic instability provides further evidence that IDC‐P is not a simple extension of dysplasia, nor does it represent invasion of Gleason grade 3 cancers into the ductal/acinar system. IDC‐P and Gleason grade 4 cancer represent late but possibly separate events in prostate cancer evolution. Prostate 44:265–270, 2000. © 2000 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/1097-0045(20000901)44:4&lt;265::AID-PROS1&gt;3.0.CO;2-I</identifier><identifier>PMID: 10951489</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>New York: John Wiley &amp; Sons, Inc</publisher><subject>Adenocarcinoma - genetics ; Adenocarcinoma - pathology ; Adenocarcinoma - surgery ; Alleles ; Biological and medical sciences ; cancer progression ; Carcinoma, Intraductal, Noninfiltrating - genetics ; Carcinoma, Intraductal, Noninfiltrating - pathology ; Carcinoma, Intraductal, Noninfiltrating - surgery ; Disease Progression ; dysplasia ; Genetic Markers - genetics ; Humans ; intraductal prostate cancer ; Loss of Heterozygosity ; Male ; Medical sciences ; Microsatellite Repeats - genetics ; Neoplasm Invasiveness ; Nephrology. Urinary tract diseases ; Prostatectomy ; Prostatic Intraepithelial Neoplasia - genetics ; Prostatic Intraepithelial Neoplasia - pathology ; Prostatic Intraepithelial Neoplasia - surgery ; Prostatic Neoplasms - genetics ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - surgery ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>The Prostate, 2000-09, Vol.44 (4), p.265-270</ispartof><rights>Copyright © 2000 Wiley‐Liss, Inc.</rights><rights>2000 INIST-CNRS</rights><rights>Copyright 2000 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4901-fce52775fc2b9d0e906e09fa32b7a638598412119aedaacebaddc400f79a1d333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F1097-0045%2820000901%2944%3A4%3C265%3A%3AAID-PROS1%3E3.0.CO%3B2-I$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F1097-0045%2820000901%2944%3A4%3C265%3A%3AAID-PROS1%3E3.0.CO%3B2-I$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1470861$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10951489$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dawkins, Hugh J.S.</creatorcontrib><creatorcontrib>Sellner, Loryn N.</creatorcontrib><creatorcontrib>Turbett, Gavin R.</creatorcontrib><creatorcontrib>Thompson, Colin A.</creatorcontrib><creatorcontrib>Redmond, Sharon L.</creatorcontrib><creatorcontrib>McNeal, John E.</creatorcontrib><creatorcontrib>Cohen, Ronald J.</creatorcontrib><title>Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>BACKGROUND Prostate ducts and acini whose lumens are filled with malignant cells represent a well‐recognized histological pattern recently termed intraductal carcinoma of the prostate (IDC‐P). These tumors are often associated with rapid disease progression, and most recur after radical surgery. Controversy exists as to whether IDC‐P should be recognized as a separate entity, an extension of high‐grade dysplasia (PIN) or invasive carcinoma as described by the Gleason grading system. This study investigates the use of molecular markers in defining the position of IDC‐P in the evolutionary hierarchy of prostate cancer progression. METHODS IDC‐P, high‐grade dysplasia, and invasive cancers from a cohort of 20 selected radical prostatectomy specimens were screened for loss of heterozygosity (LOH), using 12 polymorphic microsatellite markers frequently lost in prostate cancer. RESULTS LOH was absent in Gleason grade 3 cancer, infrequent in high‐grade dysplasia (9%) and Gleason grade 4 cancer (29%), but common in IDC‐P (60%). In IDC‐P, and to a lesser extent Gleason grade 4 cancers, multiple sites of allelic loss in individual cases were usual. CONCLUSIONS Allelic instability provides further evidence that IDC‐P is not a simple extension of dysplasia, nor does it represent invasion of Gleason grade 3 cancers into the ductal/acinar system. IDC‐P and Gleason grade 4 cancer represent late but possibly separate events in prostate cancer evolution. Prostate 44:265–270, 2000. © 2000 Wiley‐Liss, Inc.</description><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - surgery</subject><subject>Alleles</subject><subject>Biological and medical sciences</subject><subject>cancer progression</subject><subject>Carcinoma, Intraductal, Noninfiltrating - genetics</subject><subject>Carcinoma, Intraductal, Noninfiltrating - pathology</subject><subject>Carcinoma, Intraductal, Noninfiltrating - surgery</subject><subject>Disease Progression</subject><subject>dysplasia</subject><subject>Genetic Markers - genetics</subject><subject>Humans</subject><subject>intraductal prostate cancer</subject><subject>Loss of Heterozygosity</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microsatellite Repeats - genetics</subject><subject>Neoplasm Invasiveness</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prostatectomy</subject><subject>Prostatic Intraepithelial Neoplasia - genetics</subject><subject>Prostatic Intraepithelial Neoplasia - pathology</subject><subject>Prostatic Intraepithelial Neoplasia - surgery</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkt9u0zAUhyMEYmXwCsgXCHXSUmzHiZuCkKYURqSydgzE5ZHrnLSG_ClxstHn4gVxSClccINvIjm_851jf_a8mNEJo5S_YDSWPqUiHHPqVkzZmRAz8YpH4Wx2kc791YflDXsdTOgkWb7kfnrPGx1r7nsjyiX1BQvkiffI2i-UOirlD70TFwqZmMYj78fc2NZUujV1RdbY3iFWxFRto7JOt6ogWjXaVHWpSJ2Tdotk19S2VS2ScTpP_NXZOdmazdbfuAok2d7uCmWNIuNVeuX-qSpzuFu3dXssNZq4bFUf0eeks6bakLIuUHeFakipmq_Y2L6nVpXGpq_dNGitm_Ox9yBXhcUnh--p9-ntm4_JO3-xvEyTi4WvhbsqP9cYcinDXPN1nFGMaYQ0zlXA11JFwTSMp4JxxmKFmVIa1yrLtKA0l7FiWRAEp97zget6f-vQtlAaq7EoVIV1Z0EyGYk46oPXQ1C7A9oGc9g1xh1hD4xCbxJ6K9Bbgd8mQQgQ4EwCOJPwyyQEQCFZAofUMZ8emnfrErO_iIM6F3h2CCirVZE37p6M_ZMTkk4j5mI3Q-zOFLj_r8H-Ndew4aj-QHWvB78fqc4aRDKQIXy-uoTrKJA8iRbwPvgJutvV9w</recordid><startdate>20000901</startdate><enddate>20000901</enddate><creator>Dawkins, Hugh J.S.</creator><creator>Sellner, Loryn N.</creator><creator>Turbett, Gavin R.</creator><creator>Thompson, Colin A.</creator><creator>Redmond, Sharon L.</creator><creator>McNeal, John E.</creator><creator>Cohen, Ronald J.</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20000901</creationdate><title>Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression</title><author>Dawkins, Hugh J.S. ; Sellner, Loryn N. ; Turbett, Gavin R. ; Thompson, Colin A. ; Redmond, Sharon L. ; McNeal, John E. ; Cohen, Ronald J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4901-fce52775fc2b9d0e906e09fa32b7a638598412119aedaacebaddc400f79a1d333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - surgery</topic><topic>Alleles</topic><topic>Biological and medical sciences</topic><topic>cancer progression</topic><topic>Carcinoma, Intraductal, Noninfiltrating - genetics</topic><topic>Carcinoma, Intraductal, Noninfiltrating - pathology</topic><topic>Carcinoma, Intraductal, Noninfiltrating - surgery</topic><topic>Disease Progression</topic><topic>dysplasia</topic><topic>Genetic Markers - genetics</topic><topic>Humans</topic><topic>intraductal prostate cancer</topic><topic>Loss of Heterozygosity</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microsatellite Repeats - genetics</topic><topic>Neoplasm Invasiveness</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prostatectomy</topic><topic>Prostatic Intraepithelial Neoplasia - genetics</topic><topic>Prostatic Intraepithelial Neoplasia - pathology</topic><topic>Prostatic Intraepithelial Neoplasia - surgery</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dawkins, Hugh J.S.</creatorcontrib><creatorcontrib>Sellner, Loryn N.</creatorcontrib><creatorcontrib>Turbett, Gavin R.</creatorcontrib><creatorcontrib>Thompson, Colin A.</creatorcontrib><creatorcontrib>Redmond, Sharon L.</creatorcontrib><creatorcontrib>McNeal, John E.</creatorcontrib><creatorcontrib>Cohen, Ronald J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dawkins, Hugh J.S.</au><au>Sellner, Loryn N.</au><au>Turbett, Gavin R.</au><au>Thompson, Colin A.</au><au>Redmond, Sharon L.</au><au>McNeal, John E.</au><au>Cohen, Ronald J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2000-09-01</date><risdate>2000</risdate><volume>44</volume><issue>4</issue><spage>265</spage><epage>270</epage><pages>265-270</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>BACKGROUND Prostate ducts and acini whose lumens are filled with malignant cells represent a well‐recognized histological pattern recently termed intraductal carcinoma of the prostate (IDC‐P). These tumors are often associated with rapid disease progression, and most recur after radical surgery. Controversy exists as to whether IDC‐P should be recognized as a separate entity, an extension of high‐grade dysplasia (PIN) or invasive carcinoma as described by the Gleason grading system. This study investigates the use of molecular markers in defining the position of IDC‐P in the evolutionary hierarchy of prostate cancer progression. METHODS IDC‐P, high‐grade dysplasia, and invasive cancers from a cohort of 20 selected radical prostatectomy specimens were screened for loss of heterozygosity (LOH), using 12 polymorphic microsatellite markers frequently lost in prostate cancer. RESULTS LOH was absent in Gleason grade 3 cancer, infrequent in high‐grade dysplasia (9%) and Gleason grade 4 cancer (29%), but common in IDC‐P (60%). In IDC‐P, and to a lesser extent Gleason grade 4 cancers, multiple sites of allelic loss in individual cases were usual. CONCLUSIONS Allelic instability provides further evidence that IDC‐P is not a simple extension of dysplasia, nor does it represent invasion of Gleason grade 3 cancers into the ductal/acinar system. IDC‐P and Gleason grade 4 cancer represent late but possibly separate events in prostate cancer evolution. Prostate 44:265–270, 2000. © 2000 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>10951489</pmid><doi>10.1002/1097-0045(20000901)44:4&lt;265::AID-PROS1&gt;3.0.CO;2-I</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0270-4137
ispartof The Prostate, 2000-09, Vol.44 (4), p.265-270
issn 0270-4137
1097-0045
language eng
recordid cdi_proquest_miscellaneous_71764963
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Adenocarcinoma - genetics
Adenocarcinoma - pathology
Adenocarcinoma - surgery
Alleles
Biological and medical sciences
cancer progression
Carcinoma, Intraductal, Noninfiltrating - genetics
Carcinoma, Intraductal, Noninfiltrating - pathology
Carcinoma, Intraductal, Noninfiltrating - surgery
Disease Progression
dysplasia
Genetic Markers - genetics
Humans
intraductal prostate cancer
Loss of Heterozygosity
Male
Medical sciences
Microsatellite Repeats - genetics
Neoplasm Invasiveness
Nephrology. Urinary tract diseases
Prostatectomy
Prostatic Intraepithelial Neoplasia - genetics
Prostatic Intraepithelial Neoplasia - pathology
Prostatic Intraepithelial Neoplasia - surgery
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Prostatic Neoplasms - surgery
Tumors of the urinary system
Urinary tract. Prostate gland
title Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T20%3A14%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distinction%20between%20intraductal%20carcinoma%20of%20the%20prostate%20(IDC-P),%20high-grade%20dysplasia%20(PIN),%20and%20invasive%20prostatic%20adenocarcinoma,%20using%20molecular%20markers%20of%20cancer%20progression&rft.jtitle=The%20Prostate&rft.au=Dawkins,%20Hugh%20J.S.&rft.date=2000-09-01&rft.volume=44&rft.issue=4&rft.spage=265&rft.epage=270&rft.pages=265-270&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/1097-0045(20000901)44:4%3C265::AID-PROS1%3E3.0.CO;2-I&rft_dat=%3Cproquest_cross%3E71764963%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71764963&rft_id=info:pmid/10951489&rfr_iscdi=true